May 6 |
Day One Biopharmaceuticals GAAP EPS of -$0.72 misses by $0.06
|
May 6 |
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
|
May 4 |
Insider Sale at Day One Biopharmaceuticals Inc (DAWN)
|
Apr 24 |
Day One slips despite Ojemda approval as BofA says label “not a home run”
|
Apr 24 |
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
|
Apr 23 |
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
|
Apr 23 |
Day One wins FDA nod for brain cancer therapy, Ojemda
|
Mar 15 |
Companies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In Growth
|
Mar 13 |
13 Best Biotech Stocks To Buy Under $20
|
Feb 28 |
Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results
|